{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T14:57:50Z","timestamp":1775487470304,"version":"3.50.1"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,11,23]]},"DOI":"10.7759\/cureus.49307","type":"journal-article","created":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T23:01:26Z","timestamp":1700780486000},"source":"Crossref","is-referenced-by-count":1,"title":["Real-World Clinical Outcomes in Patients With Multiple Myeloma Administered With Elotuzumab-Based Treatment"],"prefix":"10.7759","author":[{"given":"Taku","family":"Kikuchi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuhiro","family":"Tsukada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Oda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moe","family":"Nomura-Yogo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomomi","family":"Takei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kota","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mizuki","family":"Ogura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Abe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenshi","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadao","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-08-107292","article-title":"Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu","volume":"112","author":"Tai YT","year":"2008","unstructured":"Tai YT, Dillon M, Song W, et al.. Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. Blood. 2008, 112:1329-37. 10.1182\/blood-2007-08-107292","journal-title":"Blood"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-4246","article-title":"CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma","volume":"14","author":"Hsi ED","year":"2008","unstructured":"Hsi ED, Steinle R, Balasa B, et al.. CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma. Clin Cancer Res. 2008, 14:2775-84. 10.1158\/1078-0432.CCR-07-4246","journal-title":"Clin Cancer Res"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0525-6","article-title":"Soluble SLAMF7 promotes the growth of myeloma cells via homophilic interaction with surface SLAMF7","volume":"34","author":"Kikuchi J","year":"2020","unstructured":"Kikuchi J, Hori M, Iha H, et al.. Soluble SLAMF7 promotes the growth of myeloma cells via homophilic interaction with surface SLAMF7. Leukemia. 2020, 34:180-95. 10.1038\/s41375-019-0525-6","journal-title":"Leukemia"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-013-1493-8","article-title":"Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC","volume":"62","author":"Collins SM","year":"2013","unstructured":"Collins SM, Bakan CE, Swartzel GD, et al.. Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC. Cancer Immunol Immunother. 2013, 62:1841-9. 10.1007\/s00262-013-1493-8","journal-title":"Cancer Immunol Immunother"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1505654","article-title":"Elotuzumab therapy for relapsed or refractory multiple myeloma","volume":"373","author":"Lonial S","year":"2015","unstructured":"Lonial S, Dimopoulos M, Palumbo A, et al.. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med. 2015, 373:621-31. 10.1056\/NEJMoa1505654","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1805762","article-title":"Elotuzumab plus pomalidomide and dexamethasone for multiple myeloma","volume":"379","author":"Dimopoulos MA","year":"2018","unstructured":"Dimopoulos MA, Dytfeld D, Grosicki S, et al.. Elotuzumab plus pomalidomide and dexamethasone for multiple myeloma. N Engl J Med. 2018, 379:1811-22. 10.1056\/NEJMoa1805762","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02815","article-title":"Elotuzumab plus pomalidomide and dexamethasone for relapsed\/refractory multiple myeloma: final overall survival analysis from the randomized phase II ELOQUENT-3 trial","volume":"41","author":"Dimopoulos MA","year":"2023","unstructured":"Dimopoulos MA, Dytfeld D, Grosicki S, et al.. Elotuzumab plus pomalidomide and dexamethasone for relapsed\/refractory multiple myeloma: final overall survival analysis from the randomized phase II ELOQUENT-3 trial. J Clin Oncol. 2023, 41:568-78. 10.1200\/JCO.21.02815","journal-title":"J Clin Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(16)30206-6","article-title":"International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar S","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, et al.. International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016, 17:328-46. 10.1016\/s1470-2045(16)30206-6","journal-title":"Lancet Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software 'EZR' for medical statistics","volume":"48","author":"Kanda Y","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant. 2013, 48:452-8. 10.1038\/bmt.2012.244","journal-title":"Bone Marrow Transplant"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/s2352-3026(22)00103-x","article-title":"Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial","volume":"9","author":"Dimopoulos MA","year":"2022","unstructured":"Dimopoulos MA, Richardson PG, Bahlis NJ, et al.. Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial. Lancet Haematol. 2022, 9:403-14. 10.1016\/s2352-3026(22)00103-x","journal-title":"Lancet Haematol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.8000","article-title":"Carfilzomib, lenalidomide, and dexamethasone (KRd) versus elotuzumab and KRd in transplant-eligible patients with newly diagnosed multiple myeloma: Post-induction response and MRD results from an open-label randomized phase 3 study","volume":"41","author":"Stuebig T","year":"2023","unstructured":"Stuebig T, Kull M, Greil R, et al.. Carfilzomib, lenalidomide, and dexamethasone (KRd) versus elotuzumab and KRd in transplant-eligible patients with newly diagnosed multiple myeloma: Post-induction response and MRD results from an open-label randomized phase 3 study. Journal of Clinical Oncology. 2023, 41:8000. 10.1200\/JCO.2023.41.16_suppl.8000","journal-title":"Journal of Clinical Oncology"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0435-7","article-title":"Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy","volume":"33","author":"Gandhi UH","year":"2019","unstructured":"Gandhi UH, Cornell RF, Lakshman A, et al.. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia. 2019, 33:2266-75. 10.1038\/s41375-019-0435-7","journal-title":"Leukemia"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2017006866","article-title":"Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma","volume":"1","author":"Casneuf T","year":"2017","unstructured":"Casneuf T, Xu XS, Adams HC 3rd, et al.. Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma. Blood Adv. 2017, 1:2105-14. 10.1182\/bloodadvances.2017006866","journal-title":"Blood Adv"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2023.283251","article-title":"Elotuzumab plus pomalidomide and dexamethasone in relapsed\/refractory multiple myeloma: a multicenter, retrospective real-world experience with 200 cases outside of controlled clinical trials","author":"Gentile M","year":"2023","unstructured":"Gentile M, Vigna E, Palmieri S, et al.. Elotuzumab plus pomalidomide and dexamethasone in relapsed\/refractory multiple myeloma: a multicenter, retrospective real-world experience with 200 cases outside of controlled clinical trials. Haematologica. 2023 Jul, 10.3324\/haematol.2023.283251","journal-title":"Haematologica"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/204845-real-world-clinical-outcomes-in-patients-with-multiple-myeloma-administered-with-elotuzumab-based-treatment","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:10:36Z","timestamp":1707509436000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/204845-real-world-clinical-outcomes-in-patients-with-multiple-myeloma-administered-with-elotuzumab-based-treatment"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,23]]},"references-count":14,"URL":"https:\/\/doi.org\/10.7759\/cureus.49307","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11,23]]}}}